Treatment of type 2 diabetes by targeting interleukin-1: a meta-analysis of 2921 patients

Kaiser AB, Zhang N, Van Der Pluijm W (2018) Global prevalence of type 2 diabetes over the next ten years (2018-2028). Diabetes 67(suppl.1):202–2LB. https://doi.org/10.2337/db18-202-LB Daousi C, Casson I, Gill G, MacFarlane I, Wilding J, Pinkney J (2006) Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J 82(966):280–284 Galaviz KI, Narayan KV, Lobelo F, Weber MB (2018) Lifestyle and the prevention of type 2 diabetes: a status report. Am J Lifestyle Med 12(1):4–20 Chrvala CA, Sherr D, Lipman RD (2016) Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control. Patient Educ Couns 99(6):926–943 Keidar A (2011) Bariatric surgery for type 2 diabetes reversal: the risks. Diab Care 34(Supplement 2):S361–S266 Gæde P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving H-H, Pedersen O (2016) Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 59(11):2298–2307 Kahn SE, Cooper ME, Del Prato S (2014) Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383(9922):1068–1083 Association AD (2019) 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2019. Diabetes Care 42(Supplement 1):S90–S102 Ahlqvist E, Storm P, Käräjämäki A, Martinell M, Dorkhan M, Carlsson A, Vikman P, Prasad RB, Aly DM, Almgren P (2018) Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. Lancet Diab Endocrinol 6(5):361–369 Wang X, Bao W, Liu J, OuYang Y-Y, Wang D, Rong S, Xiao X, Shan Z-L, Zhang Y, Yao P (2013) Inflammatory markers and risk of type 2 diabetes: a systematic review and meta-analysis. Diabetes Care 36(1):166–175 Donath MY (2014) Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov 13(6):465–476 Goldfine AB, Fonseca V, Jablonski KA, Chen Y-DI, Tipton L, Staten MA, Shoelson SE (2013) Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med 159(1):1–12 Kothari V, Galdo JA, Mathews ST (2016) Hypoglycemic agents and potential anti-inflammatory activity. J Inflamm Res 9:27–38 Mandrup-Poulsen T (2017) Immunometabolism in 2017: metabolism and the inflammasome in health and ageing. Nat Rev Endocrinol 14(2):72–74 Broz P, Dixit VM (2016) Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol 16(7):407–420 Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, Kaiser N, Halban PA, Donath MY (2002) Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J Clin Invest 110(6):851–860 Mandrup-Poulsen T (2010) IAPP boosts islet macrophage IL-1 in type 2 diabetes. Nat Immunol 11(10):881–883 Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY (2007) Interleukin-1–receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356(15):1517–1526 Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T (2009) Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diab Care 32(9):1663–1668 Mandrup-Poulsen T (2013) Interleukin-1 antagonists for diabetes. Expert Opin Investig Drugs 22(8):965–979 Huang J, Yang Y, Hu R, Chen L (2018) Anti-interleukin-1 therapy has mild hypoglycaemic effect in type 2 diabetes. Diab Obes Metab 20(4):1024–1028 Everett BM, Donath MY, Pradhan AD, Thuren T, Pais P, Nicolau JC, Glynn RJ, Libby P, Ridker PM (2018) Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. J Am Coll Cardiol 71(21):2392–2401 Ruscitti P, Alvaro S, Airò P, Battafarano N, Cantarini L, Cantatore FP, Carlino G, D'Abrosca V, Frassi M, Frediani B (2018) Anti-Interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): a multicentre, randomised, open, prospective, controlled, parallel-group trial. Lancet Available at SSRN: https://ssrncom/abstract=3258674. Accssed January 16 Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, Thuren T (2012) Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126(23):2739–2748 American Diabetes Association (2019) 6. Glycemic targets: standards of medical care in diabetes—2019. Diabetes Care 42(Supplement 1):S61–S70 Noe A, Howard C, Thuren T, Taylor A, Skerjanec A (2014) Pharmacokinetic and pharmacodynamic characteristics of single-dose canakinumab in patients with type 2 diabetes mellitus. Clin Ther 36(11):1625–1637 Cavelti-Weder C, Babians-Brunner A, Keller C, Stahel MA, Kurz-Levin M, Zayed H, Solinger AM, Mandrup-Poulsen T, Dinarello CA, Donath MY (2012) Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 35(8):1654–1662 Choudhury RP, Birks JS, Mani V, Biasiolli L, Robson MD, L'Allier PL, Gingras M-A, Alie N, McLaughlin MA, Basson CT (2016) Arterial effects of canakinumab in patients with atherosclerosis and type 2 diabetes or glucose intolerance. J Am Coll Cardiol 68(16):1769–1780 Sloan-Lancaster J, Abu-Raddad E, Polzer J, Miller JW, Scherer JC, De Gaetano A, Berg JK, Landschulz WH (2013) Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous LY2189102, a neutralizing IL-1β antibody, in patients with type 2 diabetes. Diabetes Care 36(8):2239–2246 Vickers A (2001) The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study. BMC Med Res Methodol 1(1):6 Martinez M, Bartholomew M (2017) What does it “mean”? A review of interpreting and calculating different types of means and standard deviations. Pharmaceutics 9(2):14 Rissanen A, Howard C, Botha J, Thuren T, Investigators G (2012) Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diab Obes Metab 14(12):1088–1096 Hensen J, Howard C, Walter V, Thuren T (2013) Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial. Diab Metab 39(6):524–531 Howard C, Noe A, Skerjanec A, Holzhauer B, Wernsing M, Ligueros-Saylan M, Thuren T (2014) Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies. Cardiovasc Diabetol 13(1):94 Higgins JP, Altman DG (2008) Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions: Cochrane book series:187–241 Borenstein M, Hedges LV, Higgins JP, Rothstein HR (2011) Introduction to meta-analysis. John Wiley & Sons Riley RD, Higgins JP, Deeks JJ (2011) Interpretation of random effects meta-analyses. BMJ 342:d549 IntHout J, Ioannidis JP, Rovers MM, Goeman J (2016) Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open 6(7):e010247 Koefoed M, Larsen CM, Faulenbach MV, Vaag A, Ehses JA, Donath MY, McGuire JN, Pociot F, Mandrup-Poulsen T (2010) Serum proteome pool changes in type 2 diabetic patients treated with anakinra. Clin Proteomics 6(4):153–161 Li X, Buxbaum JN (2011) Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease? Mol Neurodegener 6(1):79 Ribel-Madsen R, Friedrichsen M, Vaag A, Poulsen P (2009) Retinol-binding protein 4 in twins: regulatory mechanisms and impact of circulating and tissue expression levels on insulin secretion and action. Diabetes 58:54–60 Graham TE, Yang Q, Blüher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson P-A, Smith U (2006) Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 354(24):2552–2563 Huang R, Bai X, Li X, Zhao L, Xia M (2018) Retinol binding protein 4 impairs pancreatic beta-cell function, leading to the development of type 2 diabetes. Diabetes 67 (7) (Supplement 1). doi:https://doi.org/10.2337/db18-1826-P Oram JF, Yokoyama S (1996) Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res 37(12):2473–2491